| Revision as of 16:28, 14 October 2015 editRoches (talk | contribs)Extended confirmed users2,681 editsNo edit summary← Previous edit | Revision as of 21:43, 14 October 2015 edit undoNiceguyedc (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, Pending changes reviewers, Rollbackers413,304 editsm v1.36 - Repaired 1 link to disambiguation page - (You can help) - Heavy metalTag: WPCleanerNext edit → | ||
| Line 19: | Line 19: | ||
| Unoptimized reactions typically use 10-15 mol% of palladium; where optimized, catalyst loadings can be on the order of 0.1 mol % or below. Many exotic ligands and chiral catalysts have been reported, but they are largely not available commercially, and do not find widespread use. Much work is being done on replacing the phosphine ligands with other classes, such as Arduengo-type ] complexes, as the phosphine ligands are typically oxygen sensitive (easily oxidized) and must be handled under an inert atmosphere. Phosphines are ], sometimes requiring additional ligand. For example, Pd(PPh<sub>3</sub>)<sub>4</sub> would be supplemented with PPh<sub>3</sub> to keep the palladium coordinated despite loss of the labile phosphine ligands. | Unoptimized reactions typically use 10-15 mol% of palladium; where optimized, catalyst loadings can be on the order of 0.1 mol % or below. Many exotic ligands and chiral catalysts have been reported, but they are largely not available commercially, and do not find widespread use. Much work is being done on replacing the phosphine ligands with other classes, such as Arduengo-type ] complexes, as the phosphine ligands are typically oxygen sensitive (easily oxidized) and must be handled under an inert atmosphere. Phosphines are ], sometimes requiring additional ligand. For example, Pd(PPh<sub>3</sub>)<sub>4</sub> would be supplemented with PPh<sub>3</sub> to keep the palladium coordinated despite loss of the labile phosphine ligands. | ||
| A concern with the use of palladium in the preparation of pharmaceuticals is that traces of the |
A concern with the use of palladium in the preparation of pharmaceuticals is that traces of the ] will remain in the product. ] can be used, but solid-phase metal scavengers (] and derivatives of ]) promise more efficient separation. | ||
| In 2010, the ] was awarded to ], ] and ] for their work on palladium-catalyzed cross couplings in organic synthesis.<ref>http://nobelprize.org/nobel_prizes/chemistry/laureates/2010/</ref><ref> details of reactions</ref> | In 2010, the ] was awarded to ], ] and ] for their work on palladium-catalyzed cross couplings in organic synthesis.<ref>http://nobelprize.org/nobel_prizes/chemistry/laureates/2010/</ref><ref> details of reactions</ref> | ||
Revision as of 21:43, 14 October 2015
Palladium compounds are used as a catalyst in many coupling reactions, usually as a homogeneous catalyst. Examples include:
- Negishi coupling between an organohalide and an organozinc compound
- Heck reaction between alkenes and aryl halides
- Suzuki reaction between aryl halides and boronic acids
- Stille reaction between organohalides and organotin compounds
- Hiyama coupling between organohalides and organosilicon compounds
- Sonogashira coupling between aryl halides and alkynes, with copper(I) iodide as a co-catalyst
- The Buchwald-Hartwig amination of an aryl halide with an amine
- The Kumada coupling of grignards and aryl or vinyl halides
- The Heck-Matsuda Reaction of an arenediazonium salt with an alkene
Typical palladium catalysts used include the following compounds:
- palladium acetate, Pd(OAc)2
- tetrakis(triphenylphosphine)palladium(0), Pd(PPh3)4
- bis(triphenylphosphine)palladium(II) dichloride, PdCl2(PPh3)2
- palladium(II) dichloride
Unoptimized reactions typically use 10-15 mol% of palladium; where optimized, catalyst loadings can be on the order of 0.1 mol % or below. Many exotic ligands and chiral catalysts have been reported, but they are largely not available commercially, and do not find widespread use. Much work is being done on replacing the phosphine ligands with other classes, such as Arduengo-type carbene complexes, as the phosphine ligands are typically oxygen sensitive (easily oxidized) and must be handled under an inert atmosphere. Phosphines are labile, sometimes requiring additional ligand. For example, Pd(PPh3)4 would be supplemented with PPh3 to keep the palladium coordinated despite loss of the labile phosphine ligands.
A concern with the use of palladium in the preparation of pharmaceuticals is that traces of the toxic heavy metal will remain in the product. Column chromatography can be used, but solid-phase metal scavengers (ion exchange resins and derivatives of silica gel) promise more efficient separation.
In 2010, the Nobel Prize in Chemistry was awarded to Richard F. Heck, Ei-ichi Negishi and Akira Suzuki for their work on palladium-catalyzed cross couplings in organic synthesis.
See also
References
- http://nobelprize.org/nobel_prizes/chemistry/laureates/2010/
- PALLADIUM-CATALYZED CROSS COUPLINGS IN ORGANIC SYNTHESIS details of reactions